Yuflyma (adalimumab-aaty) vs Simlandi (adalimumab-ryvk)
Yuflyma (adalimumab-aaty) vs Simlandi (adalimumab-ryvk)
Yuflyma (adalimumab-aaty) and Simlandi (adalimumab-ryvk) are both biosimilar to the reference product Humira (adalimumab), which means they are highly similar to Humira and have been shown to have no clinically meaningful differences in terms of safety, purity, and potency. Yuflyma and Simlandi are approved for the same indications as Humira, including various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. The choice between Yuflyma and Simlandi may depend on factors such as individual patient response, insurance coverage, availability, and potentially the device used for injection, as different biosimilars may come with different types of injectors.
Difference between Yuflyma and Simlandi
| Metric | Yuflyma (adalimumab-aaty) | Simlandi (adalimumab-ryvk) |
|---|---|---|
| Generic name | Adalimumab-aaty | Adalimumab-ryvk |
| Indications | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis |
| Mechanism of action | TNF inhibitor | TNF inhibitor |
| Brand names | Yuflyma | Simlandi |
| Administrative route | Subcutaneous injection | Subcutaneous injection |
| Side effects | Infections, injection site reactions, headache, rash | Infections, injection site reactions, headache, rash |
| Contraindications | Active tuberculosis, serious infections, hypersensitivity to adalimumab or excipients | Active tuberculosis, serious infections, hypersensitivity to adalimumab or excipients |
| Drug class | Monoclonal antibody, TNF inhibitor | Monoclonal antibody, TNF inhibitor |
| Manufacturer | Celltrion Healthcare Co., Ltd. | Alvotech |
Efficacy
Introduction to Yuflyma (adalimumab-aaty)
Yuflyma (adalimumab-aaty) is a biosimilar to the reference medicine Humira (adalimumab), which is widely used in the treatment of several inflammatory conditions, including rheumatoid arthritis (RA). Yuflyma has been evaluated through rigorous clinical trials to ensure that it matches the efficacy, safety, and immunogenicity profile of its reference product. In the context of rheumatoid arthritis, Yuflyma has demonstrated the ability to reduce the signs and symptoms of the disease, inhibit the progression of structural damage, and improve physical function in adult patients.
Efficacy of Yuflyma in Rheumatoid Arthritis
The efficacy of Yuflyma for rheumatoid arthritis patients has been confirmed through comparative clinical studies with the original adalimumab. These studies have shown that Yuflyma can lead to significant improvements in RA disease activity scores, such as the DAS28-CRP, which measures disease severity. Patients treated with Yuflyma have experienced reduced joint pain and swelling, which are key indicators of the medication's efficacy in controlling the inflammatory processes associated with rheumatoid arthritis.
Introduction to Simlandi (adalimumab-ryvk)
Simlandi (adalimumab-ryvk) is another biosimilar to Humira, designed to treat the same indications, including rheumatoid arthritis. As with other biosimilars, Simlandi has undergone a thorough comparison with its reference biologic to ensure it does not have clinically meaningful differences in terms of safety, purity, and potency. For patients with rheumatoid arthritis, Simlandi offers an alternative treatment option that aims to provide equivalent outcomes to the original adalimumab formulation.
Efficacy of Simlandi in Rheumatoid Arthritis
Simlandi's efficacy in treating rheumatoid arthritis has been supported by clinical trials that have assessed its impact on disease activity, joint damage, and patient-reported outcomes. These trials have shown that Simlandi can effectively reduce symptoms of RA, leading to improvements in joint tenderness and swelling counts. Additionally, long-term use of Simlandi has been associated with sustained suppression of disease activity, suggesting that it is a viable long-term treatment option for managing rheumatoid arthritis symptoms and improving the quality of life for patients.
Regulatory Agency Approvals
Yuflyma
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Simlandi
-
Food and Drug Administration (FDA), USA
Access Yuflyma or Simlandi today
If Yuflyma or Simlandi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us